Losartan Potassium Tablet, Film Coated
Product Images NDC 50090-7945

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 50090-7945). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500907945)

Losartan Potassium 50 mg film-coated tablets packaging label from A-S Medication Solutions. The label indicates 30 tablets per container, with storage instructions to keep at 68 to 77 degrees Fahrenheit and to protect from light. The label also includes product lot number and package NDC 50090-7945-0.*

FDA Label Image

Losartanpotassiumfigure1 (Losartanpotassiumfigure1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Atenolol and Losartan Potassium. The x-axis represents study months up to 66 months, and the y-axis shows the percentage of patients up to 16%. The graph includes an adjusted risk reduction of 13% with a p-value of 0.021.*

FDA Label Image

Losartanpotassiumfigure2 (Losartanpotassiumfigure2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over 66 study months for Atenolol (dashed line) and Losartan potassium (solid line). The graph shows a lower cumulative percentage for Losartan potassium, with an adjusted risk reduction of 25% (p = 0.001). The x-axis represents study months, and the y-axis shows percentage of patients.*

FDA Label Image

Losartanpotassiumfigure3 (Losartanpotassiumfigure3)

A forest plot comparing event rates and hazard ratios with 95% confidence intervals for primary composite outcomes and fatal/non-fatal strokes between Losartan Potassium and Atenolol across patient subgroups by age, gender, race, isolated systolic hypertension (ISH), diabetes, and cardiovascular disease history. The x-axis shows hazard ratios favoring either Losartan Potassium or Atenolol.*

FDA Label Image

Losartanpotassiumfigure4 (Losartanpotassiumfigure4)

A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and Placebo groups. The x-axis represents months (0 to 48), and the y-axis represents the percent of patients with an event (0% to 60%). The chart shows a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Losartanpotassiumstructure (Losartanpotassiumstructure)

Chemical structure of losartan potassium, showing its molecular arrangement including a chlorophenyl group, hydroxymethyl moiety, biphenyl ring, tetrazole ring, and a potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.